The roles of cancer stem cells and therapeutic implications in melanoma DOI Creative Commons

Xiaoli Mu,

Yixin Zhou, Yongxin Yu

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Ноя. 14, 2024

Melanoma is a highly malignant skin tumor characterized by high metastasis and poor prognosis. Recent studies have highlighted the pivotal role of melanoma stem cells (MSCs)-a subpopulation cancer (CSCs)-in driving growth, metastasis, therapeutic resistance, recurrence. Similar to CSCs in other cancers, MSCs possess unique characteristics, including specific surface markers, dysregulated signaling pathways, ability thrive within complex microenvironment (TME). This review explored current landscape MSC research, discussing identification MSC-specific key pathways such as Wnt/β-catenin, Notch, Hedgehog (Hh), how interactions TME, hypoxia immune cells, contribute MSC-mediated drug resistance metastatic behavior. Furthermore, we also investigated latest strategies targeting MSCs, small-molecule inhibitors, immune-based approaches, novel vaccine developments, with an emphasis on their potential overcome progression improve clinical outcomes. aims provide valuable insights into roles biology offers perspectives for future research advances against this challenging disease.

Язык: Английский

Engineering nanomedicines for immunogenic eradication of cancer cells: Recent trends and synergistic approaches DOI Creative Commons
Ahmed O. Elzoghby, Omar Samir,

Hagar E. Emam

и другие.

Acta Pharmaceutica Sinica B, Год журнала: 2024, Номер 14(6), С. 2475 - 2504

Опубликована: Март 20, 2024

Resistance to cancer immunotherapy is mainly attributed poor tumor immunogenicity as well the immunosuppressive microenvironment (TME) leading failure of immune response. Numerous therapeutic strategies including chemotherapy, radiotherapy, photodynamic, photothermal, magnetic, chemodynamic, sonodynamic and oncolytic therapy, have been developed induce immunogenic cell death (ICD) cells thereby elicit boost antitumor However, many challenges hamper clinical application ICD inducers resulting in modest Here, we outline current state using nanomedicines for boosting cells. Moreover, synergistic approaches used combination with inducing remodeling TME

Язык: Английский

Процитировано

11
Decoding the Intricate Landscape of Pancreatic Cancer: Insights into Tumor Biology, Microenvironment, and Therapeutic Interventions DOI Open Access

Antonella Argentiero,

Alessandro Andriano,

Ingrid Catalina Caradonna

и другие.

Cancers, Год журнала: 2024, Номер 16(13), С. 2438 - 2438

Опубликована: Июль 2, 2024

Pancreatic ductal adenocarcinoma (PDAC) presents significant oncological challenges due to its aggressive nature and poor prognosis. The tumor microenvironment (TME) plays a critical role in progression treatment resistance. Non-neoplastic cells, such as cancer-associated fibroblasts (CAFs) tumor-associated macrophages (TAMs), contribute growth, angiogenesis, immune evasion. Although cells infiltrate TME, evade responses by secreting chemokines expressing checkpoint inhibitors (ICIs). Vascular components, like endothelial pericytes, stimulate angiogenesis support while adipocytes secrete factors that promote cell invasion, Additionally, perineural characteristic feature of PDAC, contributes local recurrence Moreover, key signaling pathways including Kirsten rat sarcoma viral oncogene (KRAS), transforming growth factor beta (TGF-β), Notch, hypoxia-inducible (HIF), Wnt/β-catenin drive Targeting the TME is crucial for developing effective therapies, strategies inhibiting CAFs, modulating response, disrupting blocking neural interactions. A recent multi-omic approach has identified signature genes associated with anoikis resistance, which could serve prognostic biomarkers targets personalized therapy.

Язык: Английский

Процитировано

5
Co-delivering irinotecan and imiquimod by pH-responsive micelle amplifies anti-tumor immunity against colorectal cancer DOI

Wenlu Yan,

Yu Li,

Yiting Zou

и другие.

International Journal of Pharmaceutics, Год журнала: 2023, Номер 648, С. 123583 - 123583

Опубликована: Ноя. 7, 2023

Язык: Английский

Процитировано

10
Nanomedicines as enhancers of tumor immunogenicity to augment cancer immunotherapy DOI
Gaidaa M. Dogheim,

Nourhan E. El Feel,

Esraa A. Abd El-Maksod

и другие.

Drug Discovery Today, Год журнала: 2024, Номер 29(3), С. 103905 - 103905

Опубликована: Янв. 29, 2024

Язык: Английский

Процитировано

4
Therapeutic Potential of Natural Compounds to Modulate WNT/β-Catenin Signaling in Cancer: Current State of Art and Challenges DOI Open Access
Anna Gajos-Michniewicz, Małgorzata Czyż

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(23), С. 12804 - 12804

Опубликована: Ноя. 28, 2024

Targeted therapies and immunotherapies have improved the clinical outcome of cancer patients; however, efficacy treatment remains frequently limited due to low predictability response development drug resistance. Therefore, novel therapeutic strategies for various types are needed. Current research emphasizes potential value targeting WNT/β-catenin dependent signaling that is deregulated in types. Targeting pathway with diverse synthetic natural agents subject a number preclinical studies trials patients. The usage nature-derived attributed their health benefits, reduced toxicity side effects compared agents. review summarizes ongoing aim target components across spectrum types, highlighting improve treatment.

Язык: Английский

Процитировано

3
Targeting Wnt/β-catenin signaling using XAV939 nanoparticles in tumor microenvironment-conditioned macrophages promote immunogenicity DOI Creative Commons
Chetan Pundkar, Ferrin Antony, Xuejia Kang

и другие.

Heliyon, Год журнала: 2023, Номер 9(6), С. e16688 - e16688

Опубликована: Май 31, 2023

The aberrant activation of Wnt/β-catenin signaling in tumor cells and immune the microenvironment (TME) promotes malignant transformation, metastasis, evasion, resistance to cancer treatments. increased Wnt ligand expression TME activates β-catenin antigen (Ag)-presenting (APCs) regulates anti-tumor immunity. Previously, we showed that dendritic (DCs) induction regulatory T cell responses over CD4

Язык: Английский

Процитировано

7
The Pro-Apoptotic Effect of Gemcitabine in Glioblastoma Multiform Cancer Model Induces by Tankyrase (TNKS) 1 Inhibitor XAV939 Through Autophagy Inhibition DOI Creative Commons
Mohammadreza Rashidi Nooshabadi,

Alireza Abdollahnezhad,

Firuzeh Badreh

и другие.

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Авг. 13, 2024

Abstract Glioblastoma multiforme (GBM) is a global malignancy with high morbidity and mortality rates, largely due to the lack of effective therapeutic alternatives. Gemcitabine (GEM) primarily used for treating GBM cancer patients, but its effectiveness limited by chemoresistance. Urgently, novel agent treatment needed. Recent research has redirected focus XAV939, small-molecule inhibitor, towards potential as an anti-cancer lung, breast, colon, cancer. However, information regarding combination therapy GEM XAV939 currently unavailable. The present study revealed that co-administration resulted in significant enhancement BAX Bcl2 ratio, caspase3, 9 activities, well inhibition tumor growth, induction apoptosis, cessation cell survival. which inhibited autophagy, led decrease concentrations proteins Beclin1, LC3II, p62. Furthermore, inhibitory effect vivo on growth was synergistic superior alone. inhibits endothelial vascular invasion, necrosis, proliferation, thereby augmenting antitumor activity cancer; this finding suggests may have

Язык: Английский

Процитировано

0
The roles of cancer stem cells and therapeutic implications in melanoma DOI Creative Commons

Xiaoli Mu,

Yixin Zhou, Yongxin Yu

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Ноя. 14, 2024

Melanoma is a highly malignant skin tumor characterized by high metastasis and poor prognosis. Recent studies have highlighted the pivotal role of melanoma stem cells (MSCs)-a subpopulation cancer (CSCs)-in driving growth, metastasis, therapeutic resistance, recurrence. Similar to CSCs in other cancers, MSCs possess unique characteristics, including specific surface markers, dysregulated signaling pathways, ability thrive within complex microenvironment (TME). This review explored current landscape MSC research, discussing identification MSC-specific key pathways such as Wnt/β-catenin, Notch, Hedgehog (Hh), how interactions TME, hypoxia immune cells, contribute MSC-mediated drug resistance metastatic behavior. Furthermore, we also investigated latest strategies targeting MSCs, small-molecule inhibitors, immune-based approaches, novel vaccine developments, with an emphasis on their potential overcome progression improve clinical outcomes. aims provide valuable insights into roles biology offers perspectives for future research advances against this challenging disease.

Язык: Английский

Процитировано

0